Athersys, Inc. (ATHXQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Z. Kasey Rosado | Interim CFO & Director | 1.51M | -- | 1974 |
| Senthil Ranganathan Ph.D. | Vice President of Technical Operations | -- | -- | -- |
| Mr. David Russ M.B.A. | Vice President of Supply Chain, Finance & Administration | -- | -- | -- |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Executive VP & Head of Global Regulatory Affairs | -- | -- | -- |
| Dr. Robert Mays Ph.D. | Executive VP, Head of Regenerative Medicine & Neuroscience Programs | -- | -- | -- |
| Mr. Rakesh Ramachandran MS | Head of Information Technology & Communications and VP | -- | -- | -- |
| Dr. Sarah Busch Ph.D. | VP of Regenerative Medicine & Head of Business Development | -- | -- | -- |
| Ms. Ellen Gurley | Manager of Corporate Communications and Investor Relations | -- | -- | -- |
Athersys, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 24
Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Corporate Governance
Upcoming Events
April 4, 2025 at 8:00 PM UTC - April 9, 2025 at 8:00 PM UTC
Athersys, Inc. Earnings Date
Recent Events
November 28, 2023 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission